Adoptive immunotherapy using clinical-grade T cells.
Institution:
University of Texas M.D. Anderson Cancer Center
Researcher(s):
Laurence Cooper, MD, PhD
Grant Type:
Innovation Grants
Type of Childhood Cancer:
Leukemia, Acute Lymphoblastic Leukemia (ALL)
Project Description:
Update 6/2014:
These publications were supported in part by funding from Alex's Lemonade Stand Foundation:
Singh H, Huls H, Kebriaei P, Cooper LJ. A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19. Immunol Rev. 2014 Jan;257(1):181-90.
Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One. 2013 May 31;8(5):e64138
Huls MH, Figliola MJ, Dawson MJ, Olivares S, Kebriaei P, Shpall EJ, Champlin RE, Singh H, Cooper LJ. Clinical application of Sleeping Beauty and artificial antigen presenting cells to genetically modify T cells from peripheral and umbilical cord blood. J Vis Exp. 2013 Feb 1;(72):e50070.
Maiti SN, Huls H, Singh H, Dawson M, Figliola M, Olivares S, Rao P, Zhao YJ, Multani A, Yang G, Zhang L, Crossland D, Ang S, Torikai H, Rabinovich B, Lee DA, Kebriaei P, Hackett P, Champlin RE, Cooper LJ. Sleeping beauty system to redirect T-cell specificity for human applications. J Immunother. 2013 Feb;36(2):112-23.
Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res. 2013 Apr;161(4):265-83.
Video:
The video below was submitted along with Dr. Cooper's final report.
